NuVasive releases $62.5M from escrow following appeals court ruling NuVasive announced the release of $62.5M from a restricted escrow account in relation to NuVasive's trademark dispute regarding the NeuroVision trade name. In January 2011, an unfavorable judgment in the amount of $60M plus attorney fees and costs was entered against NuVasive relating to its use of the NeuroVision trade name. NuVasive subsequently entered into an escrow arrangement and transferred $62.5M into a restricted escrow account to secure the judgment. In reversing the judgment against NuVasive, the Ninth Circuit Court of Appeals remanded the case for a new trial and instructed the court to assign a different judge. The plaintiff has not appealed the Court of Appeals' ruling and NuVasive has now secured the release of the $62.5M from the restricted escrow account.
NuVasive CEO news an incremental positive, says Piper Jaffray Piper Jaffray views NuVasive's naming Greg Lucier as its permanent CEO as an incremental positive despite the executive's lack direct experience in the spine industry. Piper notes its channel checks indicate no meaningful sales force disruption from the CEO transition. It reiterates an Overweight rating on NuVasive with a $56 price target.